Trastuzumab

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with HER2-positive breast cancer, according to long-term results of a randomized phase 3 trial.

SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

Gastric Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors for the disease.

Updated findings from a randomized trial yielded new insights into the optimal duration of adjuvant trastuzumab for women with HER2-positive breast cancer.

Dennis J. Slamon, MD, PhD, received the Szent-Györgyi Prize for Progress in Cancer Research.

A regimen of pembrolizumab plus trastuzumab and chemotherapy extended OS for individuals with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Paolo Tarantino, MD, speaks with Healio about future research directions in metastatic breast cancer.

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent’s manufacturer.

SAN ANTONIO — A four-therapy combination conferred clinical benefit to nearly all evaluable patients with metastatic triple-positive breast cancer, according to findings of the ASPIRE trial presented at San Antonio Breast Cancer Symposium.